Scott DeWire, PhD

Scott DeWire, PhD, is Corporate Senior Vice President and Global Head of Business Development & Licensing at Boehringer Ingelheim, leading the company’s worldwide BD&L strategy across all therapeutic areas. He is based in both Ridgefield, CT, and Cambridge, MA. Scott earned his BS in Cellular Biology from the University of Connecticut and began his scientific career at Pfizer in Groton, CT. He subsequently completed his PhD in Molecular Biology at the University of North Carolina and conducted postdoctoral research in the laboratory of Nobel Laureate Robert Lefkowitz at Duke University, focusing on G protein–coupled receptor signaling. In 2007, Scott co founded Trevena Inc., where he helped drive the discovery and development of Olinvyk®, a novel therapy for acute pain. He later joined Boehringer Ingelheim, contributing to early discovery programs that advanced into the approved medicines Skyrizi® and Spevigo®. Scott subsequently transitioned into Business Development ten years ago, where he specialized in oncology partnering before being appointed Global Head of BD&L in January 2025.